Acute myeloid leukemia (AML) is characterized by a hierarchical cellular organization, with a minor fraction of self‐renewing and probably chemotherapy‐resistant leukemic stem cells (LSCs) at the apex of this hierarchy.1, 2, 3 Within CD34‐positive leukemias, which comprise about three quarters of all AMLs, LSCs have been shown to predominantly reside in the CD34+38− cell fraction.4, 5 Since LSCs are considered being the primary cause of disease relapse in AML, successful targeting of this population is crucial to improve patient outcomes. Here, CD34 is linked to leukemia.